A new class of liquid biopsy test for earlier liver cancer detection
EvoLiver™ is the flagship blood test in our hepatology product portfolio, built on Mursla Bio's proprietary AI Precision Medicine Platform.
EvoLiver™ is designed to detect liver cancer early in high risk populations
In April 2025, EvoLiver™ received FDA Breakthrough Device Designation, the first in five years for any test in the liver cancer surveillance space.
We are advancing towards launching EvoLiver™ as a laboratory developed test (LDT) in 2026.
Our initial focus is to transform the surveillance of liver cancer in high-risk populations - the fastest growing cause of cancer related deaths.
For example, 10 million people in the United States and Europe are at high risk of developing liver cancer each year, often due to a pre-existing medical condition such as cirrhosis. These patients are enrolled in surveillance programmes for early liver cancer detection, primarily through ultrasound imaging, which is recommended twice yearly due to the fast progression of liver cancer.
However, detection rates remain low because ultrasound lacks sufficient sensitivity, particularly in overweight individuals. Additionally, poor adherence to the programme is common, as it requires a separate appointment from routine blood tests and is hindered by the known limitations of ultrasound.
